Katherine Wilemon Articles
Underutilization of cascade screening for familial hypercholesterolemia
Why cascade screening for familial hypercholesterolemia. Cascade screening in the context of dyslip- idemia refers to cholesterol testing of close relatives of individuals who fulfill genetic or phenotypic criteria for the diagnosis of famil- ial hypercholesterolemia (FH).
read more »The Rationale and Design of the CASCADE FH Registry: Expert Analysis
Familial hypercholesterolemia (FH) is a genetic disease of elevated low-density lipoprotein cholesterol (LDL-C) that affects over one million people in the U.S.1 Left untreated, FH results in a 20-fold increase in the lifetime risk of premature coronary heart disease due to high LDL-C exposure from…
read more »Familial hypercholesterolaemia: putting the patient first
Patients and their families must be proactively involved in the identification and treatment of people with familial hypercholesterolaemia (FH) – a group whose severely raised low density lipoprotein cholesterol (LDL-C) puts them at a very high risk of premature death. Founder and CEO of the…
read more »Reducing the burden of Disease and Death from Familial Hypercholesterolemia: A Call to Action
Familial hypercholesterolemia (FH) is a genetic disease characterized by substantial elevations of low-density lipoprotein cholesterol, unrelated to diet or lifestyle. Untreated FH patients have 20 times the risk of developing coronary artery disease, compared to the general population. Estimates indicate that as many as 1…
read more »FH is a family disorder
For every one patient there are an additional 8 cases of familial hypercholesterolaemia (FH) to be diagnosed – Katherine Wilemon, Founder, President and CEO of the FH Foundation: see http://thefhfoundation.org/ Underdiagnosis and undertreatment of FH are major issues. The clinical relevance is underlined by evidence…
read more »Rationale and Design of the Familial Hypercholesterolemia Foundation CAscade SCreening for Awareness and Detection
Familial hypercholesterolemia (FH) is a hereditary condition caused by various genetic mutations that lead to significantly elevated low-density lipoprotein cholesterol levels and resulting in a 20-fold increased lifetime risk for premature cardiovascular disease. Although its prevalence in the United States is 1 in 300 to…
read more »